持续病毒学应答可以降低肝硬化和肝病并发症的发生，降低肝癌(肝细胞性癌)和死亡的发生率。
Sustained virologic response can result in decreased cirrhosis and complications of liver disease, decreased rates of liver cancer (hepatocellular carcinoma), and decreased mortality.
持续性病毒学应答的最佳指标是较低的治疗前血清hbvDNA滴度和较高的谷丙转氨酶(ALT)水平。
The best indicators of sustained virologic response are low pre-treatment serum HBV DNA titers and elevated alanine aminotransferase (ALT) levels.
这类患者出现持续病毒学应答(SVR)的机率很高——大概是70%到80%，且无治疗的禁忌症，是非常好的治疗对象。
These patients have a high likelihood of SVR (Sustained Virological Response) - probably 70-80% - and in the absence of any contraindications of therapy they are very good candidates.
应用三联疗法的患者中，超过70%的患者能够达到持续病毒学应答，同时对难治性基因型患者也能获得很好的疗效。
This will comprise of direct antiviral drugs such as protease inhibitors along with peg-Interferon and ribavirin. This can provide a sustained virological response in over 70% of patients.
在两项试验中，持续的病毒学应答率为79%和80%，相比标准治疗方案，即长效干扰素联合利巴韦林的应答率50%更高。
The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin.
在两项试验中，持续的病毒学应答率为79%和80%，相比标准治疗方案，即长效干扰素联合利巴韦林的应答率50%更高。
The sustained virologic response rate was 79% and 80% in two studies, which was higher than the response rate of 50% with the standard of care with peginterferon plus ribavirin.
应用推荐